Preliminary human bioequivalence study of indidataropyrone bromide inhalation powder (chinadrugtrials.org.cn) - Oct 13, 2026 - P1 | N=16 | Not yet recruiting | Sponsor: Yangtze River Pharmaceutical Group Co., Ltd.
New P1 trial • Bronchiectasis • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
|